Now one controversial startup is halting treatment

Quick Read

For the crowd of mostly baby boomers, who’d just finished their healthy lunch of salmon fillet on a bed of grains and vegetables, the warning could not have been more dire: You’re running out of time

Quick Read

At the Recode conference in Rancho Palos Verdes, California, Jesse Karmazin, who leads the small biotech startup Ambrosia, told New Scientist that he had positive results from a preliminary trial injecting older patients with younger plasma,the liquid part of blood that doesn’t contain any cells

Quick Read

A startup called Ambrosia will fill your veins with the blood of young people and empty your pockets of $8,000

Quick Read

Joining the circulation of two mice weakened the younger one, but didn’t do much for the old one

Quick Read

Piggybacking on contentious research, the startup Ambrosia is offering blood transfusions meant to rejuvenate people

Quick Read